Tumor profiling and the incidentalome: patient decisions and risks.

摘要: In recent years, the field of oncology has witnessed rapid advancements in genetic sequencing simultaneously with steeply declining costs technology. As a result, genomics-driven cancer medicine and use tumor profiling are quickly becoming mainstays therapy. Oncology patients can benefit from by allowing selection targeted therapies tailored to their disease. However, it is increasingly recognized that process determining DNA sequence may lead incidental discovery underlying germline mutations which impact other aspects patient’s health, family. How handle ‘incidentalome’ been subject public debate, yet patient education about potential risks remains sparse. Patient perspectives clinical implications incidentalome must be specifically addressed community as expands become new standard care.